Evolent Well being (EVH) reported $621.4 million in income for the quarter ended September 2024, representing a year-over-year improve of 21.6%. EPS of $0.04 for a similar interval compares to $0.30 a 12 months in the past.
The reported income compares to the Zacks Consensus Estimate of $625.58 million, representing a shock of -0.67%. The corporate delivered an EPS shock of -86.67%, with the consensus EPS estimate being $0.30.
Whereas buyers carefully watch year-over-year modifications in headline numbers — income and earnings — and the way they evaluate to Wall Road expectations to find out their subsequent plan of action, some key metrics at all times present a greater perception into an organization’s underlying efficiency.
Since these metrics play an important function in driving the top- and bottom-line numbers, evaluating them with the year-ago numbers and what analysts estimated about them helps buyers higher undertaking a inventory’s worth efficiency.
Right here is how Evolent Well being carried out within the simply reported quarter when it comes to the metrics most generally monitored and projected by Wall Road analysts:
- Common PMPM Charges / Income per Case – Efficiency Suite: $20.97 versus the three-analyst common estimate of $21.43.
- Common PMPM Charges / Income per Case – Specialty Know-how and Providers Suite: $0.38 in comparison with the $0.37 common estimate primarily based on three analysts.
- Common PMPM Charges / Income per Case – Administrative Providers: $15.74 versus the three-analyst common estimate of $15.49.
- Common Lives on Platform / Instances – Instances: 13 thousand in comparison with the 15.1 thousand common estimate primarily based on three analysts.
- Common Lives on Platform / Instances – Efficiency Suite: 6.92 million versus the three-analyst common estimate of 6.88 million.
- Common Lives on Platform / Instances – Specialty Know-how and Providers Suite: 74.19 million versus 73.82 million estimated by three analysts on common.
- Common Lives on Platform / Instances – Administrative Providers: 1.26 million in comparison with the 1.27 million common estimate primarily based on three analysts.
- Common PMPM Charges / Income per Case – Instances: $3,113 versus $2,859.51 estimated by three analysts on common.
- Whole Income by product type- Efficiency Suite: $435.10 million versus $441.93 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a +34.4% change.
- Whole Income by product type- Instances: $41.43 million versus $43.18 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a +10.9% change.
- Whole Income by product type- Administrative Providers: $59.40 million versus the three-analyst common estimate of $58.87 million. The reported quantity represents a year-over-year change of -13.6%.
- Whole Income by product type- Specialty Know-how and Providers Suite: $85.47 million versus $81.94 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a +5.2% change.
View all Key Company Metrics for Evolent Health here>>>
Shares of Evolent Well being have returned -8.3% over the previous month versus the Zacks S&P 500 composite’s +4.9% change. The inventory at present has a Zacks Rank #3 (Maintain), indicating that it might carry out consistent with the broader market within the close to time period.
Free: 5 Shares to Purchase As Infrastructure Spending Soars
Trillions of {dollars} in Federal funds have been earmarked to restore and improve America’s infrastructure. Along with roads and bridges, this flood of money will pour into AI information facilities, renewable power sources and extra.
In, you’ll uncover 5 shocking shares positioned to revenue probably the most from the spending spree that’s simply getting began on this house.
Download How to Profit from the Trillion-Dollar Infrastructure Boom absolutely free today.
Evolent Health, Inc (EVH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.
